Investors
Corporate Profile
Genomic Health (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In early 2004, we launched our first test, Oncotype DX, which has been shown to predict the likelihood of chemotherapy benefit and the likelihood of breast cancer recurrence in a large portion of early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California.
Recent Press Releases
- June 26, 2009
Genomic Health Reports Favorable Commentary on Value of Multigene Assays From the St. Gallen Expert Consensus Meeting on the Primary Treatment of Early Breast Cancer - May 29, 2009
Genomic Health Study Shows Breast Cancers in Men Display Very Similar Gene Signatures to Those in Women - All Press Releases
DISCLAIMER
The information in the fact sheet, press releases and webcasts should be considered accurate only as of the date of the document or presentation. We disclaim any obligation to supplement or update the information in these documents or presentations.
Forward-Looking Statements
This website contains forward-looking statements. Any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including risks and uncertainties associated with the reimbursement for and adoption of Oncotype DX; commercialization of any future tests; the nature and sources of our revenues; our dependence on collaborative relationships; the regulation of Oncotype DX or any future tests we may develop by the FDA; the attributes of our products; the benefits of personalized medicine and its ability to impact treatment decisions; the outcome and success of clinical trials; the applicability of clinical results to actual outcomes; the company's beliefs regarding the potential benefits that may be obtained from additional tests; and other factors detailed from time to time in Genomic Health's periodic filings with the Securities and Exchange Commission. Genomic Health, Inc. specifically disclaims any obligation to update any forward-looking statements.
 |
 |
|
Contact InformationFor Investors: For Media: |
||
 |
 |
|
|
|
Email AlertsTo sign-up to receive email alerts for press releases, stock information, new calendar events and/or SEC filings click here. |
||
|
|